[HTML] sciencedirect.com

[HTML][HTML] Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines …

LD Anderson Jr, B Dhakal, T Jain, OO Oluwole… - … and Cellular Therapy, 2023 - Elsevier
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
被引用次数：11 相关文章

Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines …

LD Anderson, B Dhakal, T Jain… - Transplantation …, 2023 - utsouthwestern.elsevierpure.com
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
[HTML] astctjournal.org

[HTML][HTML] Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to …

LD Anderson, B Dhakal, T Jain… - … and Cellular Therapy …, 2024 - astctjournal.org
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …

Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines …

LD Anderson, B Dhakal, T Jain… - Transplantation and …, 2023 - pure.johnshopkins.edu
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …